Acknowledgements
I wish to show my gratitude to the Internal medicine resi-
dency program, to Dr Dabia Hamad Almohanadi, and I
would like to thank the patient for allowing us to share his
case
References
1. Turkina A, Wang J, Mathews V, Saydam G, Jung CW, Al Hashmi HH, et al.
TARGET: a survey of real-world management of chronic myeloid leukaemia
across 33 countries. Br J Haematol. 2020.
2. Al-Dewik NI, Morsi HM, Samara MM, Ghasoub RS, Gnanam CC, Bhaskaran
SK, et al. Is Adherence to Imatinib Mesylate Treatment Among Patients
with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes
in Qatar? Clin Med Insights Oncol. 2016;10:95-104.
3. Vezzalini M, Mafficini A, Tomasello L, Lorenzetto E, Moratti E,
Fiorini Z, et al. A new monoclonal antibody detects downregulation of
protein tyrosine phosphatase receptor type gamma in chronic myeloid
leukemia patients. J Hematol Oncol. 2017;10(1):129.
4. Al-Dewik NI, Jewell AP, Yassin MA, El-Ayoubi HR, Morsi HM. Studying
the impact of presence of point mutation, insertion mutation and
additional chromosomal abnormalities in chronic myeloid leukemia
patients treated with imatinib mesylate in the State of Qatar. QScience
Connect. 2014;2014(1).
5. Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison
CJ, et al. Chronic myeloid leukemia: reminiscences and dreams.
Haematologica. 2016;101(5):541-58.
6. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua
M, et al. Imatinib for newly diagnosed patients with chronic myeloid
leukemia: incidence of sustained responses in an intention-to-treat
analysis. J Clin Oncol. 2008;26(20):3358-63.
7. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et
al. Final 5-Year Study Results of DASISION: The Dasatinib Versus
Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients
Trial. J Clin Oncol. 2016;34(20):2333-40.
8. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga
MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase
chronic myeloid leukemia: 2-year follow-up from a randomized phase 3
trial (DASISION). Blood. 2012;119(5):1123-9.
9. Yassin MA, Nashwan AJ, Soliman AT, Yousif A, Moustafa A, AlBattah A,
et al. Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with
Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront
Therapy. Clin Med Insights Case Rep. 2015;8:77-81.
10. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S,
et al. Long-term benefits and risks of frontline nilotinib vs imatinib
for chronic myeloid leukemia in chronic phase: 5-year update of the
randomized ENESTnd trial. Leukemia. 2016;30(5):1044-54.
11. Ito Y, Miyamoto T, Chong Y, Maki T, Akashi K, Kamimura T. Nilotinib
exacerbates diabetes mellitus by decreasing secretion of endogenous
insulin. Int J Hematol. 2013;97(1):135-8.
12. Ismail AS, Yassin MA. Nilotinib-Induced Diabetes Mellitus in a Young
Female with Chronic Myeloid Leukemia. Cureus. 2020;12(9):e10277.
13. Doan V, Wang A, Prescott H. Bosutinib for the treatment of chronic
myeloid leukemia. Am J Health Syst Pharm. 2015;72(6):439-47.
14. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C,
Kim DW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic
Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol.
2018;36(3):231-7.
15. Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT,
Brummendorf TH, Smith BD, et al. Bosutinib for pretreated patients with
chronic phase chronic myeloid leukemia: primary results of the phase 4
BYOND study. Leukemia. 2020;34(8):2125-37.
16. Keller VAG, Brummendorf TH. Novel aspects of therapy with the dual
Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Expert Rev Anticancer Ther. 2012;12(9):1121-7.
17. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brummendorf TH, Porkka
K, et al. Bosutinib safety and management of toxicity in leukemia
patients with resistance or intolerance to imatinib and other tyrosine
kinase inhibitors. Blood. 2014;123(9):1309-18.
18. Cortes JE, Jean Khoury H, Kantarjian H, Brummendorf TH, Mauro MJ,
Matczak E, et al. Long-term evaluation of cardiac and vascular toxicity
in patients with Philadelphia chromosome-positive leukemias treated with
bosutinib. Am J Hematol. 2016;91(6):606-16.